Beauty Equipment,Blood Vessels Removal,Spider Vein Removal Handsome Beauty Product Co., Limited , http://www.chinabeautyproduct.com
China has developed the first dose of genetic engineering vaccine for poultry infectious diseases
The key scientific and technological development project of Hubei Province undertaken by the Yangtze University--“Development of a Vaccine for Infectious Bursal Disease Genetic Engineering†project took five years to develop, and the first genetic engineering vaccine for poultry infectious diseases was developed in China. The experts group organized by the Office of Science and Technology identified that the research project has reached an internationally advanced level and has completely independent intellectual property rights, which is of great significance and application value. Infectious bursal diseaes (IBD) is an immunosuppressive infectious disease in chickens caused by infectious bursal disease virus (IBDV) infection. It has acute and highly contagious characteristics and can be quickly found in chickens. spread. Because the immunosuppression they produce is often accompanied by immunization failures such as Newcastle disease and Marek’s disease, it often leads to high morbidity and mortality of these diseases, causing great harm to the chicken industry. As the current vaccines are mostly live vaccines that are not completely attenuated, immunosuppression often causes interference with other vaccines, and they do not provide immunity against infections of very virulent strains that have emerged in recent years, and there are disadvantages such as high production costs. Therefore, The improvement of vaccines and the development of new vaccines have become the forefront of research in the veterinary medicine industry at home and abroad. Professor Rong Jun of School of Life Sciences, School of Life Sciences, Yangtze University and Associate Professor Cheng Taiping of the Faculty of Animal Science, etc., After a five-year research, a new type of genetically engineered bursal disease gene engineering subunit oil emulsion vaccine has been successfully developed. In view of the aforementioned difficulties, this vaccine is also the first domestically developed genetically engineered vaccine for poultry infectious diseases with completely independent intellectual property rights, and has now applied for patent protection. China's Veterinary Drug Surveillance Agency conducted an immunoprotective test on three batches of laboratory trial products of the vaccine, showing that the protection rates for immune challenge were 90%, 100%, and 95%, respectively. The experimental results show that the vaccine is non-toxic, does not cause damage to the bursa of chickens, does not interfere with the immune function of other vaccines, and the production cost is lower than other inactivated vaccines currently used in China, and has high development and application value. Experts suggest that we should speed up the pilot and regional tests of our products, make products enter the domestic and foreign markets as soon as possible, and carry out the follow-up development of diagnostic kits and combined vaccines as soon as possible. Experts predict that once related products enter the market, they will have very significant social and economic benefits.